WO2006138737A8 - Methods of purifying anti a beta antibodies - Google Patents

Methods of purifying anti a beta antibodies

Info

Publication number
WO2006138737A8
WO2006138737A8 PCT/US2006/024026 US2006024026W WO2006138737A8 WO 2006138737 A8 WO2006138737 A8 WO 2006138737A8 US 2006024026 W US2006024026 W US 2006024026W WO 2006138737 A8 WO2006138737 A8 WO 2006138737A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
protein
binding
binding protein
present application
Prior art date
Application number
PCT/US2006/024026
Other languages
French (fr)
Other versions
WO2006138737A2 (en
WO2006138737A3 (en
Inventor
Ranganathan Godavarti
Timothy Iskra
Original Assignee
Elan Pharma Int Ltd
Wyeth Corp
Ranganathan Godavarti
Timothy Iskra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP06785208A priority Critical patent/EP1896506B1/en
Priority to ES06785208T priority patent/ES2402650T3/en
Application filed by Elan Pharma Int Ltd, Wyeth Corp, Ranganathan Godavarti, Timothy Iskra filed Critical Elan Pharma Int Ltd
Priority to KR1020087000127A priority patent/KR101247836B1/en
Priority to JP2008517226A priority patent/JP5270337B2/en
Priority to EA200800083A priority patent/EA015148B1/en
Priority to AU2006261185A priority patent/AU2006261185B2/en
Priority to NZ565044A priority patent/NZ565044A/en
Priority to CA002611815A priority patent/CA2611815A1/en
Priority to MX2007015952A priority patent/MX2007015952A/en
Priority to BRPI0611599-3A priority patent/BRPI0611599A2/en
Publication of WO2006138737A2 publication Critical patent/WO2006138737A2/en
Publication of WO2006138737A3 publication Critical patent/WO2006138737A3/en
Priority to NO20076082A priority patent/NO20076082L/en
Priority to IL187683A priority patent/IL187683A/en
Publication of WO2006138737A8 publication Critical patent/WO2006138737A8/en
Priority to HK08110194.5A priority patent/HK1117174A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Abstract

The present application provides methods of purifying Aβ binding proteins having a Fc region, for example, anti-Aβ antibodies or antibody fusions, by adsorbing the Aβ binding protein to a Fc binding agent, such as, for example, Protein A or Protein G, followed by a wash with a divalent cation salt buffer to remove impurities and subsequent recovery of the adsorbed Aβ binding protein. The present application also features methods of eluting the purified Aβ binding protein as well as the incorporation of the methods within a purification train. Kits comprising components for carrying out the methods and instructions for use are also provided.
PCT/US2006/024026 2005-06-17 2006-06-16 Methods of purifying anti a beta antibodies WO2006138737A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MX2007015952A MX2007015952A (en) 2005-06-17 2006-06-16 Methods of purifying anti a beta antibodies.
CA002611815A CA2611815A1 (en) 2005-06-17 2006-06-16 Methods of purifying anti a beta antibodies
KR1020087000127A KR101247836B1 (en) 2005-06-17 2006-06-16 Methods of purifying anti a beta antibodies
ES06785208T ES2402650T3 (en) 2005-06-17 2006-06-16 Anti A beta antibody purification methods
EA200800083A EA015148B1 (en) 2005-06-17 2006-06-16 METHODS OF PURIFYING Aβ BINDING PROTEIN HAVING A Fc REGION
AU2006261185A AU2006261185B2 (en) 2005-06-17 2006-06-16 Methods of purifying anti A beta antibodies
BRPI0611599-3A BRPI0611599A2 (en) 2005-06-17 2006-06-16 method for purifying a beta-binding protein and beta-binding protein
EP06785208A EP1896506B1 (en) 2005-06-17 2006-06-16 Methods of purifying anti a beta antibodies
JP2008517226A JP5270337B2 (en) 2005-06-17 2006-06-16 Method for purifying anti-Aβ antibody
NZ565044A NZ565044A (en) 2005-06-17 2006-06-16 Methods of purifying anti A beta antibodies with calcium chloride
NO20076082A NO20076082L (en) 2005-06-17 2007-11-26 Methods for purifying anti-beta antibodies
IL187683A IL187683A (en) 2005-06-17 2007-11-27 Methods of purifying anti-a beta antibodies
HK08110194.5A HK1117174A1 (en) 2005-06-17 2008-09-12 Methods of purifying anti a beta antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69182105P 2005-06-17 2005-06-17
US60/691,821 2005-06-17

Publications (3)

Publication Number Publication Date
WO2006138737A2 WO2006138737A2 (en) 2006-12-28
WO2006138737A3 WO2006138737A3 (en) 2007-03-22
WO2006138737A8 true WO2006138737A8 (en) 2007-12-13

Family

ID=37433887

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/023478 WO2006138553A2 (en) 2005-06-17 2006-06-16 Methods of purifying fc region containing proteins
PCT/US2006/024026 WO2006138737A2 (en) 2005-06-17 2006-06-16 Methods of purifying anti a beta antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2006/023478 WO2006138553A2 (en) 2005-06-17 2006-06-16 Methods of purifying fc region containing proteins

Country Status (26)

Country Link
US (3) US7825223B2 (en)
EP (3) EP2388274A1 (en)
JP (2) JP5150488B2 (en)
KR (2) KR101307614B1 (en)
CN (3) CN104926938B (en)
AR (2) AR053633A1 (en)
AU (2) AU2006259298B2 (en)
BR (2) BRPI0611600B8 (en)
CA (2) CA2611815A1 (en)
CR (2) CR9576A (en)
EA (2) EA201100177A1 (en)
EC (1) ECSP088086A (en)
ES (2) ES2402650T3 (en)
HK (1) HK1117174A1 (en)
IL (2) IL187642A (en)
MA (1) MA29609B1 (en)
MX (2) MX2007015051A (en)
MY (1) MY144484A (en)
NI (1) NI200700329A (en)
NO (2) NO20076082L (en)
NZ (1) NZ565044A (en)
RU (1) RU2415865C2 (en)
SG (1) SG162806A1 (en)
TW (2) TW200740839A (en)
WO (2) WO2006138553A2 (en)
ZA (2) ZA200710330B (en)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
KR20050118669A (en) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 Active immunization to generate antibodies to soluble a-beta
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
WO2006042158A2 (en) * 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
NZ554520A (en) * 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
WO2006066089A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GT200600031A (en) * 2005-01-28 2006-08-29 ANTI-BETA ANTIBODY FORMULATION
EP2388274A1 (en) * 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Methods of purifying anti A Beta antibodies
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
PT1976877E (en) 2005-11-30 2014-04-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
CA2632822C (en) * 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
WO2010044803A1 (en) * 2008-10-17 2010-04-22 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008011348A2 (en) * 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
HUE045898T2 (en) * 2006-08-28 2020-01-28 Ares Trading Sa Process for the purification of fc-containing proteins
MX2009002013A (en) * 2006-08-28 2009-03-09 Ares Trading Sa Process for the purification of fc-fusion proteins.
TW201708537A (en) 2006-09-13 2017-03-01 艾伯維有限公司 Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) * 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
KR20100016661A (en) * 2007-04-18 2010-02-12 얀센 알츠하이머 이뮤노테라피 Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP2010528583A (en) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム Humanized antibody against amyloid β
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CN101820911B (en) * 2007-06-12 2015-05-06 Ac免疫有限公司 Humanized antibodies to amyloid beta
EP2182983B1 (en) * 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
BRPI0818621A8 (en) * 2007-10-05 2018-01-30 Ac Immune Sa pharmaceutical composition, and methods for reducing plaque burden and plaque quantity in an individual's retinal ganglion cell layer, to prevent, treat and / or alleviate the effects of an eye disease, to diagnose an eye disease and a predisposition to an eye disease, to monitor eye disease, to predict a patient's responsiveness, and to retain or decrease eye pressure in an individual's eyes
WO2009048539A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
MX2010004219A (en) 2007-10-19 2010-08-09 Seattle Genetics Inc Cd19 binding agents and uses thereof.
CA2703279C (en) * 2007-10-30 2014-04-22 Genentech, Inc. Antibody purification by cation exchange chromatography
WO2009064424A1 (en) * 2007-11-13 2009-05-22 Rational Affinity Devices, L.L.C. Tunable affinity ligands for the separation and detection of target substances
KR101247374B1 (en) * 2008-06-26 2013-03-26 한국생명공학연구원 Novel peptides with specific binding to Fc domain of IgG and their preparation methods
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
WO2010048183A1 (en) * 2008-10-20 2010-04-29 Abbott Laboratories Antibodies that bind to il-18 and methods of purifying the same
AU2009347206C1 (en) * 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
CN104974251A (en) 2008-10-20 2015-10-14 Abbvie公司 Viral inactivation during purification of antibodies
CN104740631B (en) 2008-10-29 2019-04-16 阿布林克斯公司 The preparation of single domain antigen-binding molecule
US10118962B2 (en) 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
BRPI0923541A2 (en) 2008-12-22 2016-01-26 Hoffmann La Roche immunoglobulin purification
SG162687A1 (en) 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
US8268820B2 (en) * 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
PT2424889E (en) 2009-04-30 2015-11-12 Ablynx Nv Method for the production of domain antibodies
EP3736338A1 (en) * 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Enhanced protein purification through a modified protein a elution
KR101632312B1 (en) 2009-11-03 2016-06-21 삼성전자주식회사 Fusion protein binding specifically to constant region of antibody, preparation thereof and method for isolating antibody using the same
JP2013516180A (en) * 2009-12-31 2013-05-13 ミリアント・コーポレイション Purification of succinic acid from fermentation broth containing ammonium succinate
EP2542567B1 (en) * 2010-03-05 2020-02-12 Boehringer Ingelheim International Gmbh Selective enrichment of antibodies
BR112012020964B8 (en) * 2010-03-10 2021-08-24 Hoffmann La Roche method for producing an immunoglobulin of the igg1 or igg4 subclass
JP2013523182A (en) 2010-04-15 2013-06-17 アボット・ラボラトリーズ Amyloid beta-binding protein
RU2607368C2 (en) 2010-07-30 2017-01-10 Ац Иммуне С.А. Safe and functional humanized antibodies
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
WO2012099576A1 (en) * 2011-01-18 2012-07-26 Baxter International Inc. Measurement of anti-amyloid antibodies in human blood
CN103547589A (en) * 2011-03-29 2014-01-29 葛兰素史密斯克莱有限责任公司 Buffer system for protein purification
SG10201604554WA (en) * 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
KR20140062469A (en) * 2011-07-20 2014-05-23 젭테온 인코포레이티드 Polypeptide separation methods
ES2619677T3 (en) * 2011-10-19 2017-06-26 Roche Glycart Ag Separation method for fucosylated antibodies
EP3401337A1 (en) * 2012-09-25 2018-11-14 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
TWI596107B (en) 2013-06-25 2017-08-21 卡地拉保健有限公司 Novel purification process for monoclonal antibodies
EP3016729B1 (en) 2013-07-05 2020-03-25 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Affinity chromatography matrix
MX2016003202A (en) 2013-09-13 2016-06-07 Genentech Inc Methods and compositions comprising purified recombinant polypeptides.
JP2017520531A (en) * 2014-06-02 2017-07-27 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ Production of Fc fragment
JP6451118B2 (en) * 2014-07-17 2019-01-16 東ソー株式会社 Antibody separation method
AR101262A1 (en) * 2014-07-26 2016-12-07 Regeneron Pharma PURIFICATION PLATFORM FOR Bispecific Antibodies
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN105175548B (en) * 2015-08-13 2019-02-05 齐鲁制药有限公司 The purification process of Recombinant human vascular endothelial growth factor receptor-antibody fusion protein
HRP20211737T1 (en) * 2015-08-21 2022-02-18 F. Hoffmann - La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
EP3337818A1 (en) * 2015-08-21 2018-06-27 H. Hoffnabb-La Roche Ag Affinity chromatography purification with low conductivity wash buffer
EP3344643A4 (en) * 2015-09-04 2019-05-01 Qiagen Sciences LLC Methods for co-isolation of nucelic acids and proteins
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
CN109311948B (en) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 Method for cleaning and/or disinfecting a separation matrix
CN109311949B (en) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 Method for storing separation matrices
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
CN106519029B (en) * 2016-10-31 2020-03-17 山东泰邦生物制品有限公司 Preparation process of A β oligomer antibody
US10941178B2 (en) * 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
JP2018167260A (en) * 2017-03-29 2018-11-01 三菱ケミカル株式会社 Method for preserving ion exchanger, and purification apparatus and method for physiologically active substance
ES2887046T3 (en) 2017-08-17 2021-12-21 Just Evotec Biologics Inc Method of purification of glycosylated protein from host cell galectins and other contaminants
US11447547B1 (en) 2017-12-13 2022-09-20 Amgen Inc. Method of antigen-binding protein production
CN108048477A (en) * 2017-12-15 2018-05-18 南京理工大学 The method for preparing polypeptide based on escherichia expression system
CN109929038B (en) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Purification method of VEGF (vascular endothelial growth factor) capture agent fusion protein
US11155575B2 (en) 2018-03-21 2021-10-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbent, devices and methods
US20220314142A1 (en) 2019-07-01 2022-10-06 Pfizer Inc. Improvements to wash solutions for protein a chromatography in an antibody purification process
CN112409477B (en) * 2019-08-21 2022-11-08 广东菲鹏生物有限公司 IgM purification method
CN110724204B (en) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Method for purifying Fc fusion protein
CN113968909A (en) * 2020-07-22 2022-01-25 信达生物制药(苏州)有限公司 Method for purifying bispecific antibody
MX2023000949A (en) 2020-07-23 2023-02-22 Othair Prothena Ltd Anti-abeta antibodies.

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3689123T2 (en) 1985-11-01 1994-03-03 Xoma Corp MODULAR UNIT OF ANTIBODY GENES, ANTIBODIES MADE THEREOF AND USE.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4801687A (en) * 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE68927933T2 (en) 1988-09-02 1997-08-14 Dyax Corp PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING POINTS
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
EP1690935A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5112952A (en) * 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DK1279731T3 (en) 1991-03-01 2007-09-24 Dyax Corp Process for the development of binding mini-proteins
DE69233367T2 (en) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla LIBRARIES OF HETERODIMERIC RECEPTORS BY PHAGEMIDES
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
JP2002514919A (en) 1997-04-04 2002-05-21 バイオサイト ダイアグノスティックス，インコーポレイテッド Multivalent and polyclonal libraries
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7588766B1 (en) * 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
AU4178601A (en) 2000-02-24 2001-09-03 Univ Washington Humanized antibodies that sequester abeta peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DE60229051D1 (en) * 2001-04-30 2008-11-06 Lilly Co Eli HUMANIZED ANTIBODIES
WO2002088306A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
US20060073149A1 (en) 2001-08-17 2006-04-06 Bales Kelly R Rapid improvement of cognition in condition related to abeta
ATE417858T1 (en) * 2002-02-05 2009-01-15 Genentech Inc PROTEIN PURIFICATION
AR038568A1 (en) * 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
KR20050118669A (en) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 Active immunization to generate antibodies to soluble a-beta
US20040229330A1 (en) * 2003-02-27 2004-11-18 Bayer Pharmaceuticals Corporation Integrated method for capture and purification of tagged proteins
EP1601697B1 (en) 2003-02-28 2007-05-30 Lonza Biologics plc Antibody purification by Protein A and ion exchange chromatography
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US9469672B2 (en) * 2003-10-27 2016-10-18 Wyeth Llc Removal of high molecular weight aggregates using hydroxyapatite chromatography
SG149013A1 (en) * 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
EP2479184A3 (en) * 2003-12-17 2013-09-04 Janssen Alzheimer Immunotherapy Beta immunogenic peptide carrier conjugates and methods of producing the same
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
US20070259865A1 (en) 2004-07-14 2007-11-08 Astellas Pharma Inc. Agent for Promoting the Recovery from Dysfunction After the Onset of Central Neurological Disease
WO2006042158A2 (en) * 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
AR051800A1 (en) 2004-12-15 2007-02-07 Wyeth Corp BETA ANTIBODIES USED TO IMPROVE COGNITION
TW200636066A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
KR20070107079A (en) * 2005-01-28 2007-11-06 와이어쓰 Stabilized liquid polypeptide formulations
GT200600031A (en) * 2005-01-28 2006-08-29 ANTI-BETA ANTIBODY FORMULATION
EP2388274A1 (en) 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Methods of purifying anti A Beta antibodies
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
KR20100016661A (en) * 2007-04-18 2010-02-12 얀센 알츠하이머 이뮤노테라피 Prevention and treatment of cerebral amyloid angiopathy
EP2182983B1 (en) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE

Also Published As

Publication number Publication date
CA2611816C (en) 2014-05-27
CN104926938B (en) 2019-06-04
IL187683A (en) 2015-02-26
NO20076082L (en) 2007-12-27
TWI372763B (en) 2012-09-21
NO20076056L (en) 2008-01-11
AU2006259298B2 (en) 2012-06-14
JP2008543881A (en) 2008-12-04
WO2006138553A2 (en) 2006-12-28
ZA200710331B (en) 2009-04-29
HK1117174A1 (en) 2009-01-09
MA29609B1 (en) 2008-07-01
EP1896504A2 (en) 2008-03-12
TW200840821A (en) 2008-10-16
EP1896506B1 (en) 2013-01-02
CA2611816A1 (en) 2006-12-28
EP1896506A2 (en) 2008-03-12
US7825223B2 (en) 2010-11-02
MY144484A (en) 2011-09-30
RU2415865C2 (en) 2011-04-10
AU2006259298A1 (en) 2006-12-28
BRPI0611600B1 (en) 2021-04-13
KR101247836B1 (en) 2013-03-28
WO2006138553A3 (en) 2007-02-22
US20070082367A1 (en) 2007-04-12
EP1896504B1 (en) 2012-11-21
AU2006261185A1 (en) 2006-12-28
ES2402650T3 (en) 2013-05-07
NZ565044A (en) 2010-05-28
AU2006261185B2 (en) 2012-02-16
RU2007143162A (en) 2009-08-10
EA015148B1 (en) 2011-06-30
AR053633A1 (en) 2007-05-09
CN101365722A (en) 2009-02-11
ZA200710330B (en) 2009-12-30
IL187642A (en) 2014-08-31
IL187683A0 (en) 2008-08-07
BRPI0611599A2 (en) 2011-02-22
CN104926938A (en) 2015-09-23
MX2007015952A (en) 2008-03-07
CR9576A (en) 2008-03-06
ECSP088086A (en) 2008-02-20
NI200700329A (en) 2015-04-21
WO2006138737A2 (en) 2006-12-28
US8440799B2 (en) 2013-05-14
KR20080059371A (en) 2008-06-27
CN101213211A (en) 2008-07-02
EA201100177A1 (en) 2011-06-30
JP2008543868A (en) 2008-12-04
US7820799B2 (en) 2010-10-26
CR9582A (en) 2008-05-05
US20070072307A1 (en) 2007-03-29
AR053632A1 (en) 2007-05-09
MX2007015051A (en) 2008-01-18
TW200740839A (en) 2007-11-01
WO2006138737A3 (en) 2007-03-22
JP5150488B2 (en) 2013-02-20
KR101307614B1 (en) 2013-09-13
SG162806A1 (en) 2010-07-29
EA200800083A1 (en) 2008-06-30
KR20080023315A (en) 2008-03-13
IL187642A0 (en) 2008-03-20
CA2611815A1 (en) 2006-12-28
JP5270337B2 (en) 2013-08-21
US20110160437A1 (en) 2011-06-30
BRPI0611600B8 (en) 2021-05-25
EP2388274A1 (en) 2011-11-23
ES2405079T3 (en) 2013-05-30
BRPI0611600A2 (en) 2011-03-15

Similar Documents

Publication Publication Date Title
WO2006138737A3 (en) Methods of purifying anti a beta antibodies
EP1568710A3 (en) Antibody purification method
JP2005206602A5 (en)
IL176635A0 (en) Antibody purification
WO2006094724A3 (en) Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
WO2008150946A8 (en) HUMANIZED ANTIBODIES WHICH BIND TO Aβ (1-42) GLOBULOMER AND USES THEREOF
JP2007532477A5 (en)
WO2013177115A3 (en) Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
AR086525A1 (en) ANTIBODY PURIFICATION METHOD
WO2007011907A3 (en) Alpha-synuclein antibodies and methods related thereto
WO2006061723A3 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
WO2008008482A3 (en) Altered br3-binding polypeptides
WO2008031020A3 (en) Arginine wash in protein purification using affinity chromatography
WO2008049106A3 (en) Process for preparing unaggregated antibody fc domains
MX2023006291A (en) Methods of purifying fc-containing proteins.
MX2019015304A (en) Cation exchange chromatography wash buffer.
WO2007130535A3 (en) Novel protein fusion/tag technology
WO2002101021A3 (en) Purification of human serum albumin
WO2011104307A3 (en) Ligands for antibody purification by affinity chromatography
WO2006064373A3 (en) Methods of purifying immunologlobulins
WO2007117215A8 (en) Binder for c-reactive protein
JP5089924B2 (en) Method for purifying IgM type antibody, adsorbent for IgM type antibody recognition antigen
WO2008140580A3 (en) Specific antibody selection by selective elution conditions
EA200501217A1 (en) METHOD OF CLEANING PROTEIN OF FAMILY TRANSFORMING GROWTH FACTORS
Lannér et al. CONJUGATE BY AFFINITY

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680021639.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 187683

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006261185

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: CR2007-009582

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2611815

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/015952

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12007502848

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2008517226

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006261185

Country of ref document: AU

Date of ref document: 20060616

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087000127

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 565044

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 08004272

Country of ref document: CO

Ref document number: 272/CHENP/2008

Country of ref document: IN

Ref document number: 2006785208

Country of ref document: EP

Ref document number: 200800083

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0611599

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071217